LPath, Inc. (LPTN.OB) Receives $3 Million Grant from the National Eye Institute BRDG-SPAN Program
Lpath, Inc. announced today that it was awarded a $3 million dollar grant by the National Eye Institute’s BRDG-SPAN Program. This is the maximum amount of the program which is designed to accelerate the transition from the development to commercialization of innovative technologies that improve human health, advance the mission of NIH, and create significant economic stimulus. The funds will be used to support Phase II clinical development of Lpath’s iSONEP™ for the treatment of exudative (or wet) age related macular degeneration (AMD) and possibly other ocular disorders. AMD is a medical condition that usually affects older adults which results…